Zhang Fan, Wang Hui, Huang Liuyan, Zhang Huachun
Department of Nephrology, Long Hua Hospital, Shanghai, China
Department of Nephrology, Long Hua Hospital, Shanghai, China.
BMJ Open. 2021 Feb 11;11(2):e043011. doi: 10.1136/bmjopen-2020-043011.
An increasing number of systematic reviews and meta-analyses of clinical trials have begun to investigate the effects of exercise interventions in patients with chronic kidney disease (CKD). To systematically appraise and synthesise these results, we will conduct an overview of systematic reviews and meta-analyses.
This is a protocol for an overview of systematic reviews and meta-analyses. We will search four databases: PubMed, Embase, Web of Science Core Collection and Cochrane Central Registry of Controlled Trials. Systematic reviews and meta-analyses of clinical trials evaluating the effect of exercise interventions on patients with CKD will be included. Two independent authors will screen titles and abstracts retrieved in the literature search and select studies meeting the eligibility criteria for full-text review. The methodological quality of the included reviews will be assessed using A Measurement Tool to Assess Systematic Reviews-2. We estimate the summary effects for each meta-analyses based on the standardised mean difference and its 95% . Additionally, the heterogeneity will be assessed by evidence of small-study effect and the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation system.
Ethics approval are not required as no private information from individuals is collected. The results will be published in a peer-reviewed journal or disseminated in relevant conferences.
CRD42020223591.
越来越多关于临床试验的系统评价和荟萃分析开始研究运动干预对慢性肾脏病（CKD）患者的影响。为了系统地评估和综合这些结果，我们将进行一项系统评价和荟萃分析的概述。
这是一项系统评价和荟萃分析概述的方案。我们将检索四个数据库：PubMed、Embase、科学引文索引核心合集和Cochrane对照试验中心注册库。将纳入评估运动干预对CKD患者影响的临床试验的系统评价和荟萃分析。两位独立作者将筛选文献检索中获得的标题和摘要，并选择符合全文审查纳入标准的研究。将使用《系统评价评估测量工具-2》评估纳入综述的方法学质量。我们将根据标准化均数差值及其95% 估计每个荟萃分析的汇总效应。此外，将通过小研究效应的证据和使用推荐分级评估、制定和评价系统的证据质量来评估异质性。
由于未收集个人的私人信息，因此无需伦理批准。研究结果将发表在同行评审期刊上或在相关会议上传播。
PROSPERO注册号：CRD42020223591。
